GREY:ATBPF - Post by User
Comment by
MrMugsyon Sep 24, 2021 1:29pm
169 Views
Post# 33914662
RE:Hypothetical scenario
RE:Hypothetical scenariothemagicbox wrote: Lets say Otena is done with our current indication, which I dont believe is the case at all. But as a hypothetical, given how powerful Otena is, I bet that if chronic OA doesn't work at 75mg dose, then we just re-purpose for acute pain instead of 352 to keep company alive. I see that the focus should be on 346 since its the fatherest along in the trial stages. Everything else starts at square one unfortunately.
Its a larger market and already have Phase 2B proof of concept (with that 2-week acute time horizon) that should be easily repeatable for an acute time frame. Burn rate is still under control and we have the runway to get there. It should proceed more quickly than chronic indication as well, as the chronic is a much longer time horizon.
All IMO. Food for thought.
----------------------
ahhhhhhh ... not square 1 my friend ... there is real value in what you are saying.
October first - then we get updated - we see what's available to us - negotiations out of pause ... that's what matters now.
Magic ... Supporting info/documentation re. last conversation ... on its way to you!